Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections

• Published in: Bioengineered Vol. 5; no. 2; pp. 143 - 147
• Main Authors: Griswold, Karl E, Bement, Jenna L, Teneback, Charlotte C, Scanlon, Thomas C, Wargo, Matthew J, Leclair, Laurie W
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.03.2014; Landes Bioscience
• Subjects: Addendum; Animals; Anti-Bacterial Agents - therapeutic use; antibiotics; Bioengineering - methods; biotherapeutics; Cell Survival - drug effects; cystic fibrosis; Drug Design; drug resistance; Drug Therapy, Combination - methods; lung infection model; lysozyme; lytic enzymes; Mice; Mice, Inbred C57BL; Muramidase - genetics; Muramidase - therapeutic use; Pneumonia, Bacterial - diagnosis; Pneumonia, Bacterial - drug therapy; Pneumonia, Bacterial - microbiology; protein engineering; Protein Engineering - methods; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - physiology; Pseudomonas Infections - diagnosis; Pseudomonas Infections - drug therapy; Pseudomonas Infections - microbiology; Treatment Outcome; biotherapeutics; lytic enzymes; protein engineering; lysozyme; cystic fibrosis; Pseudomonas aeruginosa; lung infection model; drug resistance; antibiotics

There is increasing urgency in the battle against drug-resistant bacterial pathogens, and this public health crisis has created a desperate need for novel antimicrobial agents. Recombinant human lysozyme represents one interesting candidate for treating pulmonary infections, but the wild type enzyme...